Malaria is a life-threatening parasitic disease transmitted by mosquitoes. If drugs are unavailable or the parasites are resistant to them, the infection progresses rapidly to become life‐threatening. Malaria kills by infecting and destroying red blood cells and by clogging capillaries that carry blood to the brain (cerebral malaria) or other vital organs.
The parasite invades the immune system, infects the liver and red blood cells and finally develops into a form that infects other mosquitoes when they bite an infected person. Infected mosquitoes then transmit the disease when they bite other persons. It’s a self-perpetuating cycle of death. In some african areas, a child gets infected an average of 5.4 times every year!
Number of malaria-related deaths every year.
And those are the soft numbers. Most malaria deaths occur at home, in private clinics, or in informal health centers, so government data dramatically underrepresents the human cost of the disease.
Other variables must also be considered. Climate change helps increase and spread mosquito populations in Central Asia and Eastern Europe. There is also concern about rapidly-growing resistance to some commonly used anti-malarials.
Percentage of children among malaria-related deaths.
Malaria keeps more children out of school than any other disease. Many children who survive malaria may suffer from learning impairments or brain damage.
It is also a major cause of perinatal mortality. Malaria puts pregnant women at high risk of dying from complications and can also cause spontaneous abortion, premature delivery, stillbirth, severe maternal anemia and low-birth-weight babies.
World population at risk of contracting malaria.
According to the World Health Organisation (WHO), 3.2 billion people are at risk. This leads to approximately 198 million malaria cases (uncertainty range: 124 to 283 million) and an estimated 584,000 malaria deaths (uncertainty range: 367,000 to 755,000). The most vulnerable are those living in the poorest countries.
Billion $ direct loss due to malaria
In Africa, besides being a considerable health risk, malaria creates economic burdens for countries, which increases the cycle of poverty and limits economic development.
Parents frequently have to choose between working and taking care of sick children, which can have a major impact on families. No one should have to choose between caring for a sick child or feeding their brothers and sisters.
How do you help people in need to pay for drugs without jeopardizing their ability to feed themselves and their children, and maintain a roof over their heads? Artequick, an anti-malarial, could be distributed free of charge to the most needy and vulnerable, as the only way to eradicate malaria is by controlling the transmission source of the disease. It is the patient, not the mosquitoes, who need treatment.
Artequick is a highly effective new anti-malarial which is more effective than any other drug currently on the market. Here is why:
- Quick-Acting: Stops the development of Plasmodium within 2 hours.
- High Efficacy: 28-day cure rate of 97.7% in treatment of falciparum malaria.
- Low Toxicity: Fewer side effects.
- Stability: More stable than other ACTs.
- Low Cost: Now #1 in sales in private markets of Kenya, Tanzania and Nigeria.
- Protection: Effectively treats and protects patients from reinfection.
- Short regimen: Two doses. First at 0 hr and second 24hrs later.
The FEMSE Project
Artequick was used as part of the FEMSE (Fast Elimination of Malaria by Source Eradication) Project in 2007, which targeted at first 36,000 residents of Moheli (Comoros Islands). The number of cases there fell by 95%. In 2012, they did the same thing on the Island of Anjouan. There, the number of cases fell by 97%. Over the following years, the results were consolidated.